Prosecution Insights
Last updated: April 19, 2026
Application No. 18/177,660

LIGHT THERAPY FOR SPA

Non-Final OA §103
Filed
Mar 02, 2023
Examiner
DIETRICH, JOSEPH M
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sundance Spas, Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
89%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
743 granted / 918 resolved
+10.9% vs TC avg
Moderate +8% lift
Without
With
+8.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
41 currently pending
Career history
959
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
45.9%
+5.9% vs TC avg
§102
24.2%
-15.8% vs TC avg
§112
12.3%
-27.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 918 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on 9 January 2026 is acknowledged. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 2, 4, 6 – 8, 13, 15, 18, and 37 – 41 is/are rejected under 35 U.S.C. 103 as being unpatentable over Hinojosa, Jr. (US PGPUB 2006/0002105 – in IDS) in view of Sullivan (USPN 6,602,275 – in IDS). Regarding claims 1, 2, and 4, Hinojosa discloses a system for water immersion, the system comprising: a shell (e.g. 12) comprising an interior wall (e.g. 14) defining a receptacle sized and shaped to hold water (e.g. ¶ 16), the shell comprising a seat between a floor of the shell and an upper edge of the shell (e.g. Fig. 1); and a therapeutic light assembly (e.g. ¶ 19 and 22) positioned in the interior wall of the shell and between the seat and the upper edge of the shell (e.g. Fig. 1), the therapeutic light assembly comprising: a lens that allows the transmission of light (e.g. ¶ 23);a housing recessed in the interior wall of the shell (e.g. Fig. 1); and at least one LED positioned between the lens and the housing (e.g. ¶ 23); wherein in use, the therapeutic light assembly is positioned below a water line during normal use (e.g. Fig. 1), but fails to teach that the LED is an infrared LED. Sullivan teaches it is known to use a therapeutic treatment light assembly (e.g. 1), wherein the therapeutic light assembly includes a plurality of infrared LEDs and a plurality of visible red light LEDs in alternating order(e.g. col 5, line 35 – col 6 line 7 and Figs. 1A, 3A, and 5). It would have been obvious to one having ordinary skill in the art to modify the LEDs as taught by Hinojosa with the infrared LEDs as taught by Sullivan, since such a modification would provide the predictable results of decreasing inflammation of the patient. Regarding claims 6 and 7, Hinojosa discloses the LED is recessed in a bore in the housing and a wall at least partially surrounding the bore (e.g. Fig. 2). Regarding claim 8, Hinojosa discloses the claimed invention, as previously described, but fails to explicitly recite a remote device for adjusting an intensity and/or duration of light emitted. Sullivan teaches it is known to use a remote box (e.g. 20) to adjust the time and treatment. Furthermore, user interfaces that use software modules or apps in order to adjust therapy are well known in the art. It would have been obvious to one having ordinary skill in the art to modify the device as taught by Hinojosa with a remote control unit as taught by Sullivan and is known int art, since such a modification would provide the predictable results of allowing a user to easily optimize the therapy. Regarding claim 13, Hinojosa discloses the plurality of infrared LEDs and the plurality of visible light LEDs are positioned substantially along a plurality of concentric rings (e.g. Fig. 2). Regarding claims 15 and 41, Hinojosa discloses the claimed invention, as described above, but does not explicitly recite an alarm system configured to emit an alarm indicative of an operational status of the therapeutic light assembly, wherein the operational status of the therapeutic light assembly comprises an active status, an inactive status, or an intensity level. Sullivan teaches it is known to have a visible alarm (i.e. display) indicative of an operation status (e.g. col 8, lines 46 – 50). It would have been obvious to one having ordinary skill in the art to modify the device as taught by Hinojosa with the alarm system as taught by Sullivan, since such a modification would provide the predictable results of alerting a user to the status of the device, so the user can optimize the therapy. Regarding claim 18, Hinojosa discloses the therapeutic light assembly comprises a reflector plate comprising a plurality of reflector hubs, each reflector hub surrounding each one of the plurality of infrared LEDs and each of the plurality of visible light LEDs (e.g. ¶ 23). Regarding claims 37 – 40, Hinojosa in view of Sullivan discloses using specific wavelengths and having a plurality of infrared and visible wavelengths, as described above. However, Hinojosa in view of Sullivan does not explicitly recite using light wavelengths of 660nm or 850nm or having twenty infrared LEDs and twenty visible light LEDs. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the wavelengths and number of LEDs as taught by Hinojosa in view of Sullivan, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art [In re Aller, 105 USPQ 233] and/or since it has been held that a prima facie case of obviousness exists where the claimed ranges and prior art ranges do not overlap but are close enough that one skilled in the art would have expected them to have the same properties. Titanium Metals Corp. of America v. Banner, 778 F.2d 775, 227 USPQ (Please see MPEP 2144.05). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH M DIETRICH whose telephone number is (571)270-1895. The examiner can normally be reached Mon - Fri 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH M DIETRICH/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Mar 02, 2023
Application Filed
Apr 10, 2024
Response after Non-Final Action
Jan 24, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599766
Systems and Methods For Treating Gastroesophageal Reflux Disease
2y 5m to grant Granted Apr 14, 2026
Patent 12599773
POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS
2y 5m to grant Granted Apr 14, 2026
Patent 12588822
Remote Physiological Monitor
2y 5m to grant Granted Mar 31, 2026
Patent 12589254
WEARABLE CARDIOVERTER DEFIBRILLATOR WITH AI-BASED FEATURES
2y 5m to grant Granted Mar 31, 2026
Patent 12589245
SYSTEMS AND METHODS RELATED TO THE TREATMENT OF BACK PAIN
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
89%
With Interview (+8.1%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 918 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month